Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia
Open Access
- 14 November 2021
- journal article
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in Personalized Psychiatry and Neurology
- Vol. 1 (2), 21-45
- https://doi.org/10.52667/2712-9179-2021-1-2-21-45
Abstract
The purpose of this review is to analyze approaches to the treatment of depressive and negative disorders in schizophrenia in terms of their level of efficacy and safety. Materials and Methods: A search was conducted for full-text articles published over the last 10 years in PubMed, Springer, Wiley Online Library, Taylor & Francis Online, APA PsycInfo, CORE, Science Direct, and eLIBRARY.RU databases. Several articles published previously to this period were also included into the review due to their high scientific value. Results: Our review suggests that antidepressants (ADs) are effective medications and they can be prescribed to correct depressive disorders and negative symptoms in patients with schizophrenia when used in combination with antipsychotics (АPs). However, when administering ADs and АPs combinations, it is important to consider the safety profile of these combinations as well as their tolerance. Negative symptoms of schizophrenia, including those induced by a number of АP, are less amenable to correction by АDs monotherapy, which requires a long period of АPs (on average - 8 weeks), which can be limited in the real life of the patient outside the hospital. Current approaches to the therapy of depressive disorders in patients suffering from schizophrenia vary from country to country. However, most of АDs used in clinical psychiatric practice are widely used in the comorbid state under consideration. Conclusion: The efficacy and safety of АDs of the different classes considered in this review depends on their mechanisms of action, duration of admission, type of АPs taken, and specific clinical situation (acute depressive disorder, major depressive episode, or chronic depressive episode). Most promising in clinical practice are serotonin–norepinephrine reuptake inhibitors (SNRIs) and dual ADs. The use of tricyclic antidepressants (TCAs) is limited due to a higher risk of adverse drug reactions (ADRs). The use of most selective serotonin reuptake inhibitors (SSRIs) is limited due to the risk of aggravation of hallucinations (this risk being higher for patients with visual hallucinations, and lower for those with auditory hallucinations) and\or iatrogenic psychosis. These ADRs may probably occur in patients suffering from schizophrenia due to their ideal "poor metabolizer" pharmacogenetic profile, since most of the drugs considered in this review have hepatic metabolism.This publication has 98 references indexed in Scilit:
- Pharmacogenetics of SSRIs and Sexual DysfunctionPharmaceuticals, 2010
- Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysisThe British Journal of Psychiatry, 2010
- Molecular mechanisms underlying synergistic effects of SSRI–antipsychotic augmentation in treatment of negative symptoms in schizophreniaJournal of Neural Transmission, 2009
- Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XRJournal of Psychopharmacology, 2008
- Efficacy and Tolerability of Adjunctive Ziprasidone in Treatment-Resistant DepressionPublished by Physicians Postgraduate Press, Inc ,2007
- Bupropion in the Treatment of Outpatients with Asthma and Major Depressive DisorderThe International Journal of Psychiatry in Medicine, 2007
- Factors associated with complex visual hallucinations during antidepressant treatmentHuman Psychopharmacology: Clinical and Experimental, 2004
- The effect of augmentation with moclobemide on symptoms of schizophreniaInternational Clinical Psychopharmacology, 1999
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960